Applied Biologics Launches Preclinical Development Program Focused on Osteoarthritis and Other Degenerative DiseasesSCOTTSDALE, Ariz., June 11, 2026 (GLOBE NEWSWIRE) -- Applied Biologics, a biopharmaceutical company advancing novel biologic therapies for serious diseases with significant unmet medical needs, today announced the initiation of a preclinical research program focused on osteoarthritis and other degenerative diseases.
Applied Biologics Presents Interim CAMPX Clinical Trial Data at the Symposium on Advanced Wound Care (SAWC) Spring 2026Interim Findings from Prospective Randomized Controlled Trial of XWRAP® Support Continued Enrollment in Chronic Diabetic Foot Ulcer Study
Applied Biologics Receives FDA Clearance to Advance BIOxHEAL Into Phase 3 Clinical Development for Diabetic Foot UlcersSCOTTSDALE, Ariz., June 09, 2026 (GLOBE NEWSWIRE) -- Applied Biologics, a biopharmaceutical company developing novel biologic therapies for chronic wounds, tissue repair, and degenerative disease, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for BIOxHEAL, enabling advancement into Phase 3 clinical development for the treatment of diabetic foot ulcers (DFU).
